日本化学療法学会雑誌第51巻第4号

Transcription

1 Methicillin resistant Staphylococcus aureusmrsa.methicillin resistant S. epidermidismrse.0 MRSA MRSE arbekacinabkquinupristindalfopristinqprdpr vancomycin MIC0. ml Streptococcus pneumoniae penicillinpc intermediate S. pneumoniaepisppc resistant S. pneumoniaeprsp.0. PRSP cefpiromecarbapenemscbps teicoplaninteic QPRDPR 0. ml Enterococcus faecalis Enterococcus faecium TEIC linezolid MIC0. ml MRSAMRSE MIC Enterococcus casseriflavus Enterococcus gallinarum TEIC MRSEStaphylococcus haemolyticus CBPs Bacteroides fragilisprevotella spp CBPs Key words: vancomycin 000 MIC I PCs: benzylpenicillinpcg cefpirome cefoselis cefoperazonecpz cefmetazolecmz latamoxeflmoxflomoxef FMOXcefaclor cefdinir cefpodoxime cefteram cefditorenceftibutencetb cefcapenes 00 CBPs: imipenem U.S.Pharmacopeiameropenem panipenem doripenem No.S : faropenem ampicillinamoxicillinampc FRPMAGs: CEPs: cefazolin tobramycintob arbekacinabk cefotiamu. S. Pharmacopeia NQs: ofloxacin ceftriaxone ceftazidimeu. S. Pharmacopeiacefozopran ciprofloxacinu. S. PharmacopeialevofloxacinORTHO McNEIL

2 tosufloxacintflx MLs: erythromycin clarithromycinu. S. PharmacopeiarokitamycinRKM azithromycinu. S. Pharmacopeia GPTs: vancomycin teicoplaninteic : sulbactamsbtu. S. Pharmacopeia minocyclineminolinezolidlzd quinupristindalfopristinqprdpr fosfomycinfom sulfamethoxazol trimethoprimst LZDQPRDPR MANUALOFCLINICAL MICROBIOLOGYSEVENTH EDITION MIC 0 MIC MIC Staphylococcus aureus ATCC Escherichia coli ATCC Enterococcus faecalis ATCC Streptococcus pneumoniae ATCC Bacteroides fragilis ATCC Bacteroides thetaiotaomicron ATCC Mueller Hinton medium MHMDifcoS. pneumoniae MHM yeast extract 0. streptococci MHM MIC Wilkins Chalgren AgarWCADifco MIC II MIC Tables MIC Tables Staphylococcus S. aureus S. aureus MPIPC MIC. mlmethicillin susceptible S. aureus MSSA.MIC. ml methicillin resistant S. aureusmrsa.mssa MRSA Tables MSSA CEPs MIC0. ml MLs MIC0 00 ml MRSA ABKQPRDPR TEIC ST MIC0. ml LZD MIC0 MIC0. ml MIC0 ml S. aureus ABKQPRDPRTEIC ST. ml LZD MIC. ml. S. epidermidis S. epidermidis MPIPC MIC 0.0 ml methicillin susceptible S. epidermidismsse.0mic 0. ml methicillin resistant S. epidermidismr- SE0.0MSSE MRSE 0 Tables lactam MSSE MIC0. ml MRSE MIC0. ml MRSE QPRDPRABK MINO LZD MIC0. ml TEIC MIC. ml. QPRDPRABK LZD. ml QPR DPR 0. ml S. haemolyticus S. haemolyticus Table

3 000 Table Susceptibility distribution of clinical isolates of MSSA SBT MPIPC SBTCPZ 0 CMZ FMOX 0 0 S FRPM TOB ABK TFLX RKM MINO 00 0 TEIC LZD 0 QPRDPR 0 0 ST FOM Methicillin susceptible Staphylococcus aureusmpipc MIC: ml : ampicillin, SBT: sulbactamampicillin, MPIPC: oxacillin, : cefazolin, : cefotiam, : ceftriaxone, : ceftazidime, : cefozopran, : cefpirome, : cefoselis, SBTCPZ: sulbactamcefoperazone, CMZ: cefmetazole, FMOX: flomoxef, : cefaclor, : cefdinir, : cefpodoxime, : cefteram, : cefditoren, : cefcapene, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem, TOB: tobramycin, ABK: arbekacin, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : erythromycin, : clarithromycin, RKM: rokitamycin, : azithromycin, MINO: minocycline, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim, FOM: fosfomycin

4 Table Susceptibility distribution of clinical isolates of MRSA SBT MPIPC SBTCPZ CMZ 0 00 FMOX S FRPM TOB ABK TFLX RKM MINO TEIC 0 LZD QPRDPR ST FOM Methicillin resistant Staphylococcus aureusmpipc MIC: ml MIC ml : ampicillin, SBT: sulbactamampicillin, MPIPC: oxacillin, : cefazolin, : cefotiam, : ceftriaxone, : ceftazidime, : cefozopran, : cefpirome, : cefoselis, SBTCPZ: sulbactamcefoperazone, CMZ: cefmetazole, FMOX: flomoxef, : cefaclor, : cefdinir, : cefpodoxime, : cefteram, : cefditoren, : cefcapene, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem, TOB: tobramycin, ABK: arbekacin, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : erythromycin, : clarithromycin, RKM: rokitamycin, : azithromycin, MINO: minocycline, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim, FOM: fosfomycin

5 000 Table Susceptibility distribution of clinical isolates of MSSE SBT MPIPC SBTCPZ CMZ FMOX 0 S FRPM TOB ABK TFLX RKM MINO 00 TEIC 0 LZD QPRDPR 00 0 ST 00 FOM 0 Methicillin susceptible StaphylococcusepidermidisMPIPC MIC: 00 ml MIC ml : ampicillin, SBT: sulbactamampicillin, MPIPC: oxacillin, : cefazolin, : cefotiam, : ceftriaxone, : ceftazidime, : cefozopran, : cefpirome, : cefoselis, SBTCPZ: sulbactamcefoperazone, CMZ: cefmetazole, FMOX: flomoxef, : cefaclor, : cefdinir, : cefpodoxime, : cefteram, : cefditoren, : cefcapene, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem, TOB: tobramycin, ABK: arbekacin, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : erythromycin, : clarithromycin, RKM: rokitamycin, : azithromycin, MINO: minocycline, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim, FOM: fosfomycin

6 Table Susceptibility distribution of 0 clinical isolates of MRSE SBT MPIPC SBTCPZ CMZ 0 00 FMOX S FRPM TOB ABK TFLX RKM MINO 0 TEIC 0 LZD QPRDPR 00 0 ST 00 FOM Methicillin resistant StaphylococcusepidermidisMPIPC MIC: 0 ml MIC ml : ampicillin, SBT: sulbactamampicillin, MPIPC: oxacillin, : cefazolin, : cefotiam, : ceftriaxone, : ceftazidime, : cefozopran, : cefpirome, : cefoselis, SBTCPZ: sulbactamcefoperazone, CMZ: cefmetazole, FMOX: flomoxef, : cefaclor, : cefdinir, : cefpodoxime, : cefteram, : cefditoren, : cefcapene, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem, TOB: tobramycin, ABK: arbekacin, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : erythromycin, : clarithromycin, RKM: rokitamycin, : azithromycin, MINO: minocycline, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim, FOM: fosfomycin

7 000 Table Susceptibility distribution of clinical isolates of Staphylococcus haemolyticus SBT MPIPC SBTCPZ CMZ 00 FMOX S FRPM TOB ABK TFLX RKM MINO 0 0 TEIC LZD QPRDPR ST 00 FOM 00 : ampicillin, SBT: sulbactamampicillin, MPIPC: oxacillin, : cefazolin, : cefotiam, : ceftriaxone, : ceftazidime, : cefozopran, : cefpirome, : cefoselis, SBTCPZ: sulbactamcefoperazone, CMZ: cefmetazole, FMOX: flomoxef, : cefaclor, : cefdinir, : cefpodoxime, : cefteram, : cefditoren, : cefcapene, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem, TOB: tobramycin, ABK: arbekacin, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : erythromycin, : clarithromycin, RKM: rokitamycin, : azithromycin, MINO: minocycline, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim, FOM: fosfomycin

8 Table Susceptibility distribution of 0 clinical isolates of Staphylococcus saprophyticus SBT MPIPC SBTCPZ CMZ FMOX S FRPM TOB ABK TFLX RKM MINO 0 0 TEIC LZD 0 QPRDPR ST FOM 0 : ampicillin, SBT: sulbactamampicillin, MPIPC: oxacillin, : cefazolin, : cefotiam, : ceftriaxone, : ceftazidime, : cefozopran, : cefpirome, : cefoselis, SBTCPZ: sulbactamcefoperazone, CMZ: cefmetazole, FMOX: flomoxef, : cefaclor, : cefdinir, : cefpodoxime, : cefteram, : cefditoren, : cefcapene, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem, TOB: tobramycin, ABK: arbekacin, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : erythromycin, : clarithromycin, RKM: rokitamycin, : azithromycin, MINO: minocycline, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim, FOM: fosfomycin

9 000 Table Susceptibility distribution of clinical isolates of Staphylococus lugdunensis MIC ml SBT MPIPC 00 0 SBTCPZ 0 0 CMZ FMOX 0 S FRPM TOB ABK TFLX RKM MINO TEIC LZD 0 QPRDPR ST FOM 0 : ampicillin, SBT: sulbactamampicillin, MPIPC: oxacillin, : cefazolin, : cefotiam, : ceftriaxone, : ceftazidime, : cefozopran, : cefpirome, : cefoselis, SBTCPZ: sulbactamcefoperazone, CMZ: cefmetazole, FMOX: flomoxef, : cefaclor, : cefdinir, : cefpodoxime, : cefteram, : cefditoren, : cefcapene, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem, TOB: tobramycin, ABK: arbekacin, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : erythromycin, : clarithromycin, RKM: rokitamycin, : azithromycin, MINO: minocycline, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim, FOM: fosfomycin

10 Table Susceptibility distribution of clinical isolates of Staphylococcus warneri MIC ml SBT MPIPC SBTCPZ CMZ FMOX 0 0 S FRPM TOB ABK TFLX RKM MINO TEIC 0 0 LZD QPRDPR 0 0 ST FOM 00 SBT: strains : ampicillin, SBT: sulbactamampicillin, MPIPC: oxacillin, : cefazolin, : cefotiam, : ceftriaxone, : ceftazidime, : cefozopran, : cefpirome, : cefoselis, SBTCPZ: sulbactamcefoperazone, CMZ: cefmetazole, FMOX: flomoxef, : cefaclor, : cefdinir, : cefpodoxime, : cefteram, : cefditoren, : cefcapene, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem, TOB: tobramycin, ABK: arbekacin, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : erythromycin, : clarithromycin, RKM: rokitamycin, : azithromycin, MINO: minocycline, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim, FOM: fosfomycin

11 000 Table Susceptibility distribution of clinical isolates of Staphylococcus capitis MIC ml SBT MPIPC 0 00 SBTCPZ CMZ 00 FMOX 00 S FRPM TOB ABK TFLX RKM MINO 00 TEIC LZD QPRDPR 0 ST FOM MIC ml : ampicillin, SBT: sulbactamampicillin, MPIPC: oxacillin, : cefazolin, : cefotiam, : ceftriaxone, : ceftazidime, : cefozopran, : cefpirome, : cefoselis, SBTCPZ: sulbactamcefoperazone, CMZ: cefmetazole, FMOX: flomoxef, : cefaclor, : cefdinir, : cefpodoxime, : cefteram, : cefditoren, : cefcapene, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem, TOB: tobramycin, ABK: arbekacin, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : erythromycin, : clarithromycin, RKM: rokitamycin, : azithromycin, MINO: minocycline, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim, FOM: fosfomycin

12 Table 0 Susceptibility distribution of clinical isolates of miscellaneous coagulase negative staphylococci* MIC ml SBT MPIPC SBTCPZ CMZ 0 FMOX 0 S FRPM TOB ABK TFLX RKM MINO 00 0 TEIC LZD 0 QPRDPR 0 ST FOM 0 00 *S. caprae strains, S. hominis strains, strain each of S. cohnii, S. hyicus, S. schleiferi, and S. simulans : ampicillin, SBT: sulbactamampicillin, MPIPC: oxacillin, : cefazolin, : cefotiam, : ceftriaxone, : ceftazidime, : cefozopran, : cefpirome, : cefoselis, SBTCPZ: sulbactamcefoperazone, CMZ: cefmetazole, FMOX: flomoxef, : cefaclor, : cefdinir, : cefpodoxime, : cefteram, : cefditoren, : cefcapene, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem, TOB: tobramycin, ABK: arbekacin, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : erythromycin, : clarithromycin, RKM: rokitamycin, : azithromycin, MINO: minocycline, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim, FOM: fosfomycin

13 000 Table Susceptibility distribution of 0 clinical isolates of Streptococcus pyogenes AMPC SBT CPZ CMZ FMOX 00 0 S FRPM TFLX MINO 00 TEIC LZD QPRDPR 0 0 ST : ampicillin, AMPC: amoxicillin, SBT: sulbactamampicillin, : cefazolin, : cefotiam, : ceftriaxone, : ceftazidime, CPZ: cefoperazone, : cefozopran, : cefpirome, : cefoselis, CMZ: cefmetazole, FMOX: flomoxef, : cefaclor, : cefdinir, : cefpodoxime, : cefteram, : cefditoren, : cefcapene, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : erythromycin, : clarithromycin, : azithromycin, MINO: minocycline, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim QPRDPR ABKLZD MIC0. ml. ml TEIC MIC0 ml MIC ml. S. saprophyticus S. saprophyticus 0 Table lactam MIC0. ml lactam RKM MLs MIC. ml

14 Table Susceptibility distribution of clinical isolates of Streptococcus agalactiae AMPC SBT CPZ CMZ FMOX 0 S FRPM TFLX MINO 0 00 TEIC LZD QPRDPR 0 ST : ampicillin, AMPC: amoxicillin, SBT: sulbactamampicillin, : cefazolin, : cefotiam, : ceftriaxone, : ceftazidime, CPZ: cefoperazone, : cefozopran, : cefpirome, : cefoselis, CMZ: cefmetazole, FMOX: flomoxef, : cefaclor, : cefdinir, : cefpodoxime, : cefteram, : cefditoren, : cefcapene, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : erythromycin, : clarithromycin, : azithromycin, MINO: minocycline, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim S. lugdunensis S. lugdunensis Table lactam MIC0. ml lactam MLsTOB MIC. ml S. warneri S. warneri Table MLs FOM TOB MIC0. ml MIC

15 000 ml TEIC MIC ml S. capitis S. capitis Table MIC0. ml ABKQPRDPR MINOTEIC LZD. mlst. ml. ml MIC0 Other coagulase negative Staphylococci S. caprae S. hominis S. cohnii S. hyicus S. schleiferi S. simulans Table 0 MINOABKQPRDPR TEIC MIC0. ml lactam MLs FOM S. caprae S. simulans CBPsNQs RKM MLs MIC. ml Streptococcus S. pyogenes S. pyogenes 0 Table CBPs MIC ml AMPC S 00 MIC0 0.0 ml MLsMIC: 0. ml.0minomic:. ml. S. agalactiae S. agalactiae Table MINO MIC0. ml NQsMIC:. ml.mino. S. pneumoniae S. pneumoniae PCG MIC 0.0 ml penicillinpc susceptible S. pneumoniaepssp.mic 0.0 ml 0. ml PC intermediate S. pneumoniaepisp.mic. ml PC resistant S. pneumoniaeprsp 0.PSSPPISP PRSP 0 Tables PSSP lactam MIC0 0. ml CBPs MIC0 0.0 ml CBPs MIC0 PISP mlprsp ml lactam MIC0 PSSP PISP PRSP TEICQPRDPR LZD PSSPPISP PRSP MIC0 NQs PSSP PRSP PRSP ml MIC MLs PSSP PSSP PRSP PSSP PISP PRSP MIC0 MIC0 S. mitis groups. sanguis group S. mitis groups. sanguis group Table S. mitis CBPs lactam MLsMINO ST TEICTFLXQPRDPR MIC0 0. ml S. anginosus group S. anginosus group Table lactam 0. ml MIC0 CBPs 0.0 ml MLs Enterococcus E. faecalis E. faecalis Table TEICLZD MIC ml MIC0. ml NQs MLs ml MIC 0.. TEIC. ml E. faecium E. faecium Table

16 Table Susceptibility distribution of clinical isolates of penicillin susceptible Streptococcus pneumoniaepssp PCG SBT AMPC CPZ CMZ 0 FMOX S FRPM TFLX RKM MINO TEIC LZD QPRDPR 0 ST PCG MIC: 00 ml PCG: benzylpenicillin, : ampicillin, SBT: sulbactamampicillin, AMPC: amoxicillin, : cefazolin, : cefotiam, : ceftriaxone, : ceftazidime, CPZ: cefoperazone, : cefozopran, : cefpirome, : cefoselis, CMZ: cefmetazole, FMOX: flomoxef, : cefaclor, : cefdinir, : cefpodoxime, : cefteram, : cefditoren, : cefcapene, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : erythromycin, : clarithromycin, RKM: rokitamycin, : azithromycin, MINO: minocycline, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim

17 000 Table Susceptibility distribution of clinical isolates of penicillin intermediate Streptococcus pneumoniaepisp PCG SBT AMPC CPZ CMZ FMOX 0 0 S FRPM TFLX RKM MINO TEIC LZD QPRDPR 0 0 ST 0 PCG MIC: 0 ml PCG: benzylpenicillin, : ampicillin, SBT: sulbactamampicillin, AMPC: amoxicillin, : cefazolin, : cefotiam, : ceftriaxone, : ceftazidime, CPZ: cefoperazone, : cefozopran, : cefpirome, : cefoselis, CMZ: cefmetazole, FMOX: flomoxef, : cefaclor, : cefdinir, : cefpodoxime, : cefteram, : cefditoren, : cefcapene, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : erythromycin, : clarithromycin, RKM: rokitamycin, : azithromycin, MINO: minocycline, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim

18 Table Susceptibility distribution of clinical isolates of penicillin resistant Streptococcus pneumoniaeprsp PCG SBT AMPC 0 0 CPZ CMZ FMOX S FRPM TFLX RKM MINO TEIC LZD QPRDPR 0 ST PCG MIC: ml PCG: benzylpenicillin, : ampicillin, SBT: sulbactamampicillin, AMPC: amoxicillin, : cefazolin, : cefotiam, : ceftriaxone, : ceftazidime, CPZ: cefoperazone, : cefozopran, : cefpirome, : cefoselis, CMZ: cefmetazole, FMOX: flomoxef, : cefaclor, : cefdinir, : cefpodoxime, : cefteram, : cefditoren, : cefcapene, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : erythromycin, : clarithromycin, RKM: rokitamycin, : azithromycin, MINO: minocycline, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim

19 000 Table Susceptibility distribution of clinical isolates of the Streptococcus mitis groupstreptococcus sanguis group SBT CPZ CMZ 00 FMOX 0 S FRPM TFLX MINO 00 TEIC LZD QPRDPR 0 ST strains S. mitis strains, S. oralis strains, strain each of S. sanguis, S. parasanguis, and S. gordonii : ampicillin, SBT: sulbactamampicillin, : cefazolin, : cefotiam, : ceftriaxone, : ceftazidime, CPZ: cefoperazone, : cefozopran, : cefpirome, : cefoselis, CMZ: cefmetazole, FMOX: flomoxef, : cefaclor, : cefdinir, : cefpodoxime, : cefteram, : cefditoren, : cefcapene, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : erythromycin, : clarithromycin, : azithromycin, MINO: minocycline, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim TEICLZDQPRDPR MIC ml TEIC LZD QPRDPR. ml E. avium E. avium 0 Table 0 ST TEICTFLX MIC0. ml ST TFLX ml

20 Table Susceptibility distribution of clinical isolates of the Streptococcus anginosus group SBT CPZ CMZ FMOX 0 S FRPM TFLX MINO 00 TEIC LZD QPRDPR 0 0 ST 00 0 S. anginosus strains, S. constellatus strains, S. intermedius strains : ampicillin, SBT: sulbactamampicillin, : cefazolin, : cefotiam, : ceftriaxone, : ceftazidime, CPZ: cefoperazone, : cefozopran, : cefpirome, : cefoselis, CMZ: cefmetazole, FMOX: flomoxef, : cefaclor, : cefdinir, : cefpodoxime, : cefteram, : cefditoren, : cefcapene, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : erythromycin, : clarithromycin, : azithromycin, MINO: minocycline, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim MIC TEIC. ml E. raffinosus E. raffinosus Table ST TEIC. ml E. casseriflavus E. gallinarum E. casseriflavus E. gallinarum

21 000 Table Susceptibility distribution of clinical isolates of Enterococcus faecalis FRPM 0 0 TFLX TEIC 0 LZD QPRDPR ST MIC ml : ampicillin, : cefozopran, : cefpirome, : cefoselis, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : erythromycin, : clarithromycin, : azithromycin, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristin dalfopristin, ST: sulfamethoxazole trimethoprim Table Susceptibility distribution of clinical isolates of Enterococcus faecium TFLX TEIC LZD QPRDPR 0 0 ST 0 00 MIC ml : ampicillin, : imipenem, : meropenem, : panipenem, : doripenem, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim

22 Table 0Susceptibility distribution of 0 clinical isolates of Enterococcus avium TFLX 0 TEIC LZD 0 QPRDPR 0 0 ST 0 : ampicillin, : imipenem, : meropenem, : panipenem, : doripenem, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim Table Susceptibility distribution of clinical isolates of Enterococcus raffinosus TFLX TEIC LZD QPRDPR ST 00 0 MIC ml : ampicillin, : imipenem, : meropenem, : panipenem, : doripenem, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim Table E. casseriflavus NQs ST E. gallinarum lactamsnqsst vanc.. ml MIC Peptostreptococcus spp. P. anaerobius 0 P. micros P. magnus P. asaccharolyticus P. hydrogenalis P. vaginalis P. bamesae P. ivorii 0 Table

23 000 Table Susceptibility distribution of chinical isolates of Enterococcus casseliflavus and Enterococcus gallinarum E. casseliflavus strains TFLX 0 TEIC LZD QPRDPR ST 0 E. gallinarum strains TFLX 0 TEIC LZD QPRDPR ST 0 00 : ampicillin, : imipenem, : meropenem, : panipenem, : doripenem, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim Peptostreptococcus spp MIC0 0. ml. ml MIC0 CETB CEPs ml MIC CBPs. ml MIC P. anaerobius P. bamesae. ml P. bamesae C. difficile C. difficile Table C. difficile MIC0:. ml PCGMIC0:. ml P. acnes P. acnes Table S 00 MIC0

24 Table Susceptibility distribution of clinical isolates of Peptostreptococcus spp CMZ 00 LMOX FMOX CETB S FRPM *P. anaerobius, 0strains, P. micros strains, strains each of P. magnus, and P. asaccharolyticus, P. hydrogenalis strains, strain each of P. vaginalis, P. bamesae, and P. ivorii : ceftazidime, : cefozopran, : cefpirome, : cefoselis, CMZ: cefmetazole, LMOX: latamoxef, FMOX: flomoxef, : cefaclor, : cefdinir, : cefpodoxime, : cefditoren, CETB: ceftibuten, : cefcapene, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem, : vancomycin Table Susceptibility distribution of clinical isolates of Clostridium difficile PCG FMOX PCG: benzylpenicillin, FMOX: flomoxef, : imipenem, : meropenem, : panipenem, : doripenem, : vancomycin 0.0 ml. ml B. fragilis B. fragilis Table FRPM MIC0 0. ml CBPs. ml. ml MIC0 CEPs LMOXFMOX. ml MIC0 Other B. fragilis group B. thetaiotaomicron B. distasonis B. uniformis B. vulgatus Other B. fragilis group Table B. fragilis FRPM MIC0... ml Prevotella spp.

25 000 Table Susceptibility distribution of clinical isolates of Propionibacterium acnes FMOX CETB S :cefotiam, FMOX:flomoxef, :cefaclor, :cefdinir, :cefpodoxime, : cefteram, :cefditoren, CETB:ceftibuten, : cefcapene, :vancomycin Table Susceptibility distribution of clinical isolates of Bacteroides fragilis SBTCPZ CMZ LMOX FMOX S FRPM 00 0 : ceftazidime, : cefozopran, : cefpirome, : cefoselis, SBTCPZ: sulbactamcefoperazone, CMZ: cefmetazole, LMOX: latamoxef, FMOX: flomoxef, : cefdinir, : cefpodoxime, : cefditoren, : cefcapene, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem P. bivia P. melaninogenica P. intermedia P. oralis P. loesheii P. buccae P. corporis P. oris Table CBPs MIC0 0. ml FMOX MIC0. ml CEPs MIC0 00 ml FMOX 00 ml MIC P. bivia III 000 LZD QPRDPR resistant

26 Table Susceptibility distribution of clinical isolates of miscellaneous members of the Bacteroides fragilis group* SBTCPZ CMZ 0 0 LMOX FMOX 00 0 S FRPM 0 *B. thetaiotaomicron strains, B. distasonis strains, B. uniformis strains, B. vulgatus strains : ceftazidime, : cefozopran, : cefpirome, : cefoselis, SBTCPZ: sulbactamcefoperazone, CMZ: cefmetazole, LMOX: latamoxef, FMOX: flomoxef, : cefdinir, : cefpodoxime, : cefditoren, : cefcapene, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem Table Susceptibility distribution of clinical isolates of Prevotella spp FMOX *P. bivia strains, P. melaninogenica strains, P. intermedia strains, strains each of P. oralis, and P. loescheii, straineach of P. buccae, P. corporis, and P. oris : ceftazidime, : cefozopran, : cefpirome, : cefoselis, FMOX: flomoxef, : imipenem, : meropenem, : panipenem, : doripenem EnterococciVRE LZD National Committee for Clinical Laboratory StandardsNC- CLS MIC ml S. aureusmsse E. faecalis E. casseriflavus MIC. ml LZD MRSA Tsiodras VRE Gonzales E. faecalis E. faecium Johnson QPRDPR NS MIC ml E. faecalis E. raffinosus. ml MIC Enterococcus MIC. ml Fluit MRSA MIC ml

27 000 Sanches MRSA MRSEmethicillin resistant S. haemolyticusmrsh other methicillin resistant coagulase negative StaphylococciMRCNS MRSA TEIC NS TEIC ml ml TEIC. ml MIC MRSE 0 S. haemolyticus S. warneri. ml MIC vanc E. casseriflavus E. gallinarum Sanches Staphylococcus TEIC MRSE.MRSH., Staphylococcus TEIC 00 vana MRSA Morbidity and Mortality Weekly ReportMMWR: 00 MMWR 0: 000 Centers for Disease Control and PreventionCDC S. aureus MRSA MRSA MRSA MRSA ABKQPRDPR ST. ml ABK MIC ml QPRDPR Diekema S. epidermidis MRSE MRSE S. epidermidis Coagulase negative staphylococcicns ABKLZDQPRDPR TEIC MRSE S. haemolyticus TEIC S. aureus S. pyogenes lactam S. pyogenes MLs Farrell 0 MLs.. S. pneumoniae PISP PRSPPISPPCG MIC ml PRSPPCG MIC. ml PISPPRSP PISPPRSP 000 PISPPRSP PRSP Felmingham Adam Doern Low Perez Trallero PSSPPISPPRSP Ubukata NS PCG MIC PCG MIC PSSP

28 PRSP PBP S. pneumoniae PISP+PRSP : 00 :. 0 : 0. :. :. :. :. PSSP 0 0 PRSP CBPsTFLX TEIC 0. ml MIC0 NQs ml MIC Yokota. VRE Karlowsky 0 E. faecalis E. faecium. VRE E. faecalis, E. faecium, E. avium, E. raffinosus, E. casseriflavus, E. gallinarum E. casseriflavus, E. gallinarum E. casseriflavus, E. gallinarum TEICLZD. ml E. faecalis MIC. ml MIC ml NQs MIC: ml Enterococcus NQs Peptostreptococcus spp MIC0 0. ml MIC0. ml MIC. ml P. bamesae C. difficile MIC0. ml Pelaez. B. fragilis MIC0 0.0 ml. ml MIC0. ml. ml B. fragilis CBPs Wexler MIC0 0 Prevotella spp CBPs MIC0 MIC0 B. fragilis MRSA CNS vana VRSA VISA VRE PRSP LZD QPRDPR

29 000 : Chemotherapy : : Chemotherapy : 0 : Chemotherapy : 0 : Chemotherapy : : Chemotherapy : : : 0000 : : Manual of Clinical Microbiology Seventh Edition: American Society for MicrobiologyWashingtonD. C., MIC : MICChemotherapy : 0 MIC : MICChemotherapy : 0 National Committee for Clinical Laboratory StandardsNS: TwelfthInformational Supplement M00 SPerformance Standards for Antimicrobial Susceptibility Testing. WaynePA: NS00 Tsiodras SGold H SSakoulasG et al.: Linezolid resistance in a clinical isolate of Staphylococcus aureus. LANCET : 0000 Gonzales RSchreckenberger P CGraham M Bet al.: Infections due to vancomycin resistant Enterococcus faecium resistant to linezolid. LANCET : 00 Johnson A PTysall LStockdale M Wet al.: Emerging Linezolid Resistant Enterococcus faecalis and Enterococcus faecium Isolated from Two Austrian Patients in the Same Intensive Care Unit. Eur. J. Clin. Microbiol. Infect. Dis. : 00 Fluit A CWielders C L CVerhoef Jet al.: Epidemiology and Susceptibility of 0 Staphylococcus aureus Isolates from University Hospitals Participating in the European SENTRY Study. J. Clin. Micribiol. : 00 Sanches I SMato RLancastre H Det al.: Patterns of Multidrug Resistance among Methicillin Resistant Hospital Isolates of Coagulase Positive and Coagulase Negative Staphylococci Collected in the International Multicenter Study RESIST in and. Microb. Drug Resist. : 000 : 000 Jpn. J. Antibiotics : 00 Diekema D JPfaller M AJones R Net al.: Trends in antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections in the USACanada and Latin America. Int. J. Antimicrob. Agents. : 000 : 000 Jpn. J. Antibiotics : Farrell D JMorrissey IBakker Set al.: Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROTEKT 000 study. J. Antimicrob. Chemother. 0S : 00 : 000 Jpn. J. Antibiotics : 00 : cefpodoxime Jpn. J. Antibiotics : 00 Felmingham DReinert R RHirakata Y., et al.: Increasing prevalence of antimicrobial resistance amaong isolates of Streptococcus pneumoniae from the PROTECT surveillance studyand comparative in vitro activity of the ketolidetelithromycin. J. Antimicrob. Chemother. 0S : 00 Adam D: Grobal antibiotic resistance in Streptococcus pneumoniaej. Antimicrob. Chemother. 0:T : 00 Doern G VHeilmann K PHuynh H Ket al.: Antimicrobial Resistance among Clinical Isolates of Streptococcus pneumoniae in the United States during 000Including a Comparison of Resistance Rate since. Antimicrob. Agents Chemother. : 00 LowDEAzovedo J DWeiss Ket al.: Antimicrobial Resistance among Clinical Isolates of Streptococcus pneumoniae in Canada during 000. Antimicrob. Agents Chemother. : 000 Perez Trallero EFernandez Mazarrasa CGarcia Rey Cet al.: Antimicrobial Susceptibilities of

30 Streptococcus pneumoniae and 0 Streptococcus pyogenes Isolates and Their Ecological Relationships: Results of a Year Multicenter Surveillance Study in Spain. Antimicrob. Agents Chemother. : 000 Ubukata KMuraki TIgarashi Aet al.: Identification of Penicillin and other Beta Lactam Resistance in Streptococcus pneumoniae by Polymerase Chain Reaction. J. Infect. Chemother. : 0 Yokota SSato KKuwahara Oet al.: Fluoroquinolone Resistant Streptococcus pneumoniae Strains Occur Frequently in Elderly Patients in Japan. Antimicrob. Agents Chemother. : 00 0 Karlowsky J AKelly L JCritchley I Aet al.: Determining Linezolid s Baseline In Vitro Activity in Canada Using Gram Positive Clinical Isolates Collected prior to Its National Rerease. Antimicrob. Agents Chemother. : 00 : VanAE. faecalis : : VRE linezolid 0: 000 : VRE : 000 Pelaez TAlcala LAlonso Ret al.: Reassessment of Clostridium difficile Susceptibility to Metronidazole and Vancomycin. Antimicrob. Agents Chemother. : 000 Wexler H MMolitoris DSt. John Set al.: InVitro Activities of Faropenem against Strains of Anaerobic Bacteria. Antimicrob. Agents Chemother. : 00 Surveillance of susceptibility of clinical isolates of various bacterial species to antibacterial s Antimicrobial activity against gram positive cocci and anaerobic bacteria isolated in 000 Isamu YoshidaYoshiji KimuraIsao Higashiyama Giichi Sugimori and Yoshinori Yamano Discovery Research LaboratoriesShionogi & Co., Ltd., Futaba cho ToyonakaOsaka 0Japan The activity of various antibacterial s against clinical isolates of strains of gram positive cocci0 speciesand strains of anaerobic bacteria specieswas assessed by determining their agar dilution MICs. The strains testedwere clinical isolates obtained in 000 at facilities in Japan. Methicillin resistant strains accounted for. of the Staphylococcus aureus and for.0 of the Staphylococcus epidermidisarbekacinabkquinupristindalfopristinqprdprand vancomycin had high antibacterial activity against methicillin resistant S. aureusmrsaand methicillin resistant S. epidermidismrsewith MIC0 values. ml. PenicillinPC intermediate strains and PC resistant strains accounted for. and 0.respectivelyof the Streptococcus pneumoniae CefpiromecarbapenemsCBPsteicoplaninTEICand QPRDPR displayed high antibacterial activity against PRSPinhibiting the growth of all strains at 0. ml. TEICand linezolid were effective against Enterococcus faecalis and Enterococcus faecium with MIC0 values. ml. No resistant strains were found among the gram positive coccus isolates testedincluding MRSA MRSEand Enterococcus speciesexcept Enterococcus casseriflavus and Enterococcus gallinarumhowever TEIC resistant strains were detected in some speciessuch as MRSE and Staphylococcus haemolyticus Among the anaerobescbps displayed potent antibacterial activity against all anaerobic bacteriahowever thedecrease in susceptibility of Bacteroides fragilis and Prevotella spp. to CBPs should be noted.